USE OF BOTULOTOXIN TYPE A IN THE TREATMENT OF PRIMARY HEADACHE
Annotatsiya
For the treatment of chronic daily headache (CDH) a Botulotoxin type A was used. After treatment, 34% of patients had no extravasal effect, and 66% had moderate. Normalization of venous outflow was noted in 58% of patients, of whom only 10% had changes in their severity after the procedure. The obtained results testify to an improvement in the cerebral blood flow indicators of patients with CDH against the background of injections of botulinum toxin type A. The purpose of the study was to determine the efficacy of botulotoxin type A influence on chronic daily headache (CDH) flow. The objectives were to assess the dynamics of the clinical signs of CDH, the chances of the effect of BTA on the activity of antinociceptive systems and cerebral blood flow.